aTyr Pharma (LIFE) Reports Q2 Loss of $0.74/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to aTyr Pharma (LIFE) Reports Q2 Loss of $0.74/Share

aTyr Pharma Announces Second Quarter 2015 Operating Results

August 12, 2015 4:10 PM EDT

SAN DIEGO, Aug. 12, 2015 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced operating results for the second quarter and first half of 2015.

Resolaris, a first-in-class protein therapeutic in adult patients with facioscapulohumeral muscular dystrophy (FSHD), is currently in an ongoing Phase 1b/2 clinical trial, with initial results expected in late 2015 or early 2016.  The Company is on track to initiate a Phase 1b/2 clinical trial in early onset FSHD patients in the third... More